Self-regulating networks dictate the genetic program of tumor cells

September 25, 2012

Scientists at Charité – Universitätsmedizin Berlin could explain a yet unknown regulatory network that controls the growth of tumor cells. Understanding such networks is an important task in molecular tumor biology in order to decode the relationships between the determinants defining which molecules are produced and in what quantities, in both normal and tumor cells. The study is published in the journal Molecular Systems Biology.

The growth of a tumor and its reaction to specifically targeted therapy is dictated by changes in its genetic material (mutations) encoding special signal molecules. These molecules activate the genetic program of tumor cells via branched signalingpathways and influence all processes needed for cell division, the mobility of cells and metastasis. Significant steering elements of these tumor-specific programs are called transcription factors. These are molecules that selectively control the transcription of the cell's genetic information (DNA) into and enable production of proteins . Altogether a complex network of mutually regulating transcription factors is activated.

Whereas the signal network in human tumors has already been characterized very well, it is hardly understood how transcription factors cooperate and regulate each other. In order to explain this transcription factor network, the scientists used a approach. A complex experimental data set—in which the in were systematically disrupted—was analyzed with the help of mathematical modeling. As a result, interactions within the network could be reconstructed and the network controlling tumor growth clarified.

"Contrary to a current assumption, the results show that no superordinate transcription factor exists that controls the activity of other factors as a master regulator," explains Prof. Reinhold Schäfer, head of the Laboratory for Molecular Tumor Pathology and deputy director of the Charité Comprehensive Cancer Center. Instead, two hierarchical groups of interacting factors exist. Each of them activates gene sets needed for growth and cancer-specific properties of the cells. The results indicate that new therapeutic approaches against tumors must target multiple rather than singular factors and consider the network structures.

Explore further: What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

More information: Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol. 2012 Jul 31;8:601. doi: 10.1038/msb.2012.32

Related Stories

What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

July 6, 2011
Glioblastoma is the most common and most lethal form of brain tumor in people. Research published in the International Journal of Computational Biology and Drug Design offers a novel way to determine what biological functions ...

Researchers and colleagues identify PHF20, a regulator of gene P53

August 24, 2012
Researchers at Moffitt Cancer Center and colleagues have identified PHF20, a novel transcriptional factor, and clarified its role in maintaining the stability and transcription of p53, a gene that allows for both normal cell ...

Disappearance of genetic material allows tumor cells to grow

August 4, 2011
Malignant Sézary syndrome is characterized by the reproduction of a special type of white blood cells in the skin of male and female patients. In contrast to most other skin lymphomas, patients with Sézary syndrome ...

Recommended for you

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.